FibroGen (FGEN) & Compugen (CGEN) Head to Head Analysis

FibroGen (NASDAQ: FGEN) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares FibroGen and Compugen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FibroGen $179.58 million 21.81 -$61.68 million ($2.04) -23.36
Compugen $710,000.00 195.88 -$31.50 million ($0.71) -3.83

Compugen has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

57.2% of FibroGen shares are held by institutional investors. Comparatively, 17.4% of Compugen shares are held by institutional investors. 13.6% of FibroGen shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for FibroGen and Compugen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroGen 0 2 5 1 2.88
Compugen 0 0 1 0 3.00

FibroGen presently has a consensus price target of $65.67, suggesting a potential upside of 37.81%. Compugen has a consensus price target of $14.00, suggesting a potential upside of 414.71%. Given Compugen’s stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than FibroGen.

Profitability

This table compares FibroGen and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FibroGen -120.00% -47.36% -23.51%
Compugen N/A -70.91% -60.92%

Risk and Volatility

FibroGen has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Compugen has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Summary

FibroGen beats Compugen on 8 of the 15 factors compared between the two stocks.

FibroGen Company Profile

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.